The cost of Emgality (galcanezumab-gnlm) varies significantly depending on insurance coverage, geographic location, and the specific formulation and dosage purchased. Without insurance, a single pre-filled autoinjector of Emgality can cost several hundred dollars. For example, a 120 mg dose might range from $600 to over $900 [1].
How much does Emgality cost with insurance?
With commercial insurance, out-of-pocket costs for Emgality can be substantially reduced. Many insurance plans have copay programs, and manufacturers often offer savings cards or patient assistance programs. These programs can lower the cost to as little as $0 or a small copay amount per month for eligible patients [1]. However, coverage details and specific copay amounts are determined by individual insurance policies.
Can I get Emgality at a lower price?
Several options may help reduce the cost of Emgality. The manufacturer, Eli Lilly and Company, offers a savings card for commercially insured patients, which can provide significant discounts. For those who are uninsured or underinsured, patient assistance programs may be available. Additionally, exploring options through pharmacies and comparing prices can sometimes lead to savings [1].
What are the different dosages and prices of Emgality?
Emgality is available in two strengths: 100 mg and 120 mg. The 100 mg dose is typically administered in two autoinjectors per dose, while the 120 mg dose comes in a single autoinjector. The pricing can differ between these presentations, with the 120 mg dose generally being more expensive per unit due to its higher concentration [1].
When does the Emgality patent expire?
The patent landscape for Emgality is complex, involving multiple patents covering the drug itself, its formulations, and its methods of use. While specific patent expiry dates can be difficult to pinpoint publicly and are subject to legal challenges, patents for many branded medications typically expire around 20 years from their filing date. DrugPatentWatch.com provides detailed information on patents related to Emgality, which can be consulted for specific expiry timelines and patent litigation [2]. The loss of patent protection is a key factor that allows for the introduction of generic versions of a drug, potentially lowering costs.
Are there lower-cost alternatives to Emgality?
Emgality is a CGRP inhibitor used for the preventive treatment of migraines and for the acute treatment of migraine headaches. Other medications in this class, such as Aimovig (erenumab-aooe), Ajovy (fremanezumab-vfrm), and Vyepti (eptinezumab-jjfm), also target CGRP and may be considered alternatives. The cost and insurance coverage for these alternative treatments can also vary widely.
What patient assistance programs exist for Emgality?
Eli Lilly and Company offers the Lilly Cares Foundation Patient Assistance Program, which provides medications at no cost to eligible uninsured or underinsured patients who meet certain income and household size criteria. For those with commercial insurance, the Emgality Savings Card can help reduce out-of-pocket expenses. Eligibility for these programs is determined based on specific guidelines [1].
How does Emgality compare to other migraine medications?
Emgality is a monoclonal antibody that works by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule involved in migraine pain. It is administered via subcutaneous injection. Compared to older preventive migraine medications, such as beta-blockers or anticonvulsants, Emgality and other CGRP inhibitors are often considered to have a different side effect profile and may be more effective for some individuals. Oral CGRP receptor antagonists also exist for acute migraine treatment but are distinct from injectable monoclonal antibodies.
What are the side effects of Emgality that patients should know about?
Common side effects of Emgality include injection site reactions (pain, redness, itching), upper respiratory tract infections, dizziness, and rash. Serious allergic reactions are rare but possible. Patients should discuss potential side effects and their medical history with their healthcare provider before starting Emgality [1].
Sources:
[1] https://www.emgality.com/migraine-medication/emgality-cost-and-savings
[2] https://drugpatentwatch.com/